FIELD: medicine.
SUBSTANCE: presented phospholipid liposomes of irinotecan sucrose octasulphate with improved storage stability, with corresponding methods of production.
EFFECT: irinotecan liposomes can provide reduced formation of lysophosphatidylcholine (lyso-PC) during storage and before administration to a patient.
49 cl, 9 ex, 15 tbl, 23 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| STABILIZED PHARMACEUTICAL COMPOSITIONS OF CAMPTOTHECIN | 2016 |
|
RU2732567C2 |
| LIPOSOMAL COMPOSITIONS APPLICABLE FOR DRUG DELIVERY | 2005 |
|
RU2574926C2 |
| LIPOSOMAL COMPOSITIONS USED FOR DRUG DELIVERY | 2015 |
|
RU2757110C2 |
| LIPOSOMAL COMPOSITION FOR APPLICATION IN PERITONEAL DIALYSIS | 2013 |
|
RU2609860C2 |
| NEW THERMALLY-SENSITIVE LIPOSOMES CONTAINING THERAPEUTIC AGENTS | 2008 |
|
RU2497499C2 |
| LIPOSOME HAVING INNER AQUEOUS PHASE AND CONTAINING SULPHOBUTYL ESTER CYCLODEXTRIN SALT | 2010 |
|
RU2575793C2 |
| LIPOSOMAL COMPOSITION, NEUTRAL LIPOPOLYMER AND METHOD FOR ELONGATION OF LIPOSOME CIRCULATING TIME | 2000 |
|
RU2250911C2 |
| LYOPHILIZED LIPOSOMES | 2012 |
|
RU2780489C2 |
| LIOPHILIZED LIPOSOMES | 2012 |
|
RU2648753C2 |
| LIPOSOMAL COMPOSITION AND PHARMACEUTICAL COMPOSITION | 2018 |
|
RU2734900C1 |
